Cipla Claims Success With Advair Trial
Indian Firm Has Warned FDA Review Could Last Two Years
Cipla is celebrating an “important milestone” for the company after the successful completion of a Phase III clinical trial comparing its proposed Advair generic with GSK’s brand in the US. Management has cautioned that approval will be a way off yet, however.
